ReElement Technologies stock soars after securing $1.4B government deal
Investing.com - Cantor Fitzgerald maintained its Neutral rating and $79.00 price target on Alexandria Real Estate (NYSE:ARE), currently trading at $65.80, following the company’s third-quarter 2025 earnings report. According to InvestingPro analysis, the stock appears undervalued with strong fundamentals including a healthy current ratio of 3.24.
The life science real estate investment trust significantly reduced its 2025 funds from operations (FFO) guidance, which Cantor Fitzgerald described as "a meaningful reduction" representing years of challenges in funding its large development pipeline primarily through asset sales.
Cantor Fitzgerald noted that Alexandria faces ongoing pressure from "still substantial Life Science oversupply" combined with a biotech marketplace that "may not be improving fast enough" to alleviate the company’s challenges.
The research firm indicated that Alexandria has "essentially commenced a full earnings reset for 2025" while also providing insights into 2026 that suggest current analyst estimates may be overly optimistic.
While Cantor Fitzgerald acknowledged uncertainty regarding potential regulatory impacts on Alexandria’s business, the firm maintained its neutral stance on the stock with the unchanged $79.00 price target.
In other recent news, Alexandria Real Estate has been the subject of several analyst assessments and corporate developments. Cantor Fitzgerald lowered its price target for the company to $79.00 from $88.00, maintaining a Neutral rating, citing persistent challenges despite Alexandria’s strong real estate and scientific talent. Jefferies initiated coverage with a Hold rating and set a price target of $80.00, identifying Alexandria as the largest Life Science REIT within its coverage. BNP Paribas Exane downgraded the stock to Underperform, setting a price target of $82.00 after revising its financial projections for the company.
Additionally, Cantor Fitzgerald initiated a Neutral rating with a price target of $88.00, based on a 2026 estimated AFFO multiple of 12.8x, which is below the industry average. In corporate developments, Alexandria Real Estate announced a partnership with Eli Lilly to open the Lilly Gateway Labs San Diego at its One Alexandria Square campus. This new biotech hub is part of Eli Lilly’s shared innovation hub concept to support biotechnology companies in developing medicines. The San Diego location marks the fourth Gateway Labs site in the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.